- The Asia-Pacific oligonucleotides synthesis market is a rapidly expanding sector within the broader life sciences industry, driven by the increasing application of synthetic nucleic acids in diverse fields such as drug discovery, molecular diagnostics, and genetic engineering. This growth is significantly fuelled by the region's expanding biopharmaceutical sector and rising investments in R&D
- The escalating demand for oligonucleotides is primarily driven by the widespread adoption of genomics research, growing focus on personalized medicine and gene therapies, and a rising preference for precise and highly specific molecular tools in diagnostics and therapeutics. These converging factors are accelerating the uptake of oligonucleotides synthesis solutions, thereby significantly boosting the industry's growth across Asia-Pacific
- China dominates the Asia-Pacific oligonucleotides synthesis market, with a market share of 37.5% supported by large-scale production facilities, growing domestic demand for precision medicine, and active government initiatives in synthetic biology
- India is expected to witness the highest CAGR of 14.2% in the Asia-Pacific oligonucleotides synthesis market driven by its expanding pharmaceutical industry, increasing focus on genomic research, and strong support through national biotechnology initiatives
- Synthesized oligonucleotide products segment dominates the Asia-Pacific oligonucleotides synthesis market with a market share of 49.50% in 2024. This dominance is driven by the direct demand for custom and catalog oligonucleotides used across various applications, including gene synthesis, PCR primers, siRNA, and antisense oligonucleotides
